Cybin (CYBN) said Monday that data from a phase 2 study show that CYB003, a potential adjunctive treatment for major depressive disorder, offers "sustained relief" through one year.
By 12 months, response rates for two 16-milligram doses of the drug given three weeks apart were 100% while 71% of the eight study participants were in remission, the company said.
Cybin said it recently initiated a phase 3 trial to evaluate CYB003's effectiveness and safety in a larger number of patients. The drug earlier received Breakthrough Therapy Designation from the US Food and Drug Administration for major depressive disorder, Cybin added.
The company also said it expects to report phase 2 results for CYB004 as a potential treatment for generalized anxiety disorder in Q1.
Cybin shares were up 11% in recent premarket activity.
Price: 12.89, Change: +1.29, Percent Change: +11.12
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。